Floatz logo

cc-5013

Pre-transplant Purging

M.D. Anderson Cancer CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Pre-transplant Purging cohort.

Asset / SponsorPhaseRating
TACROLIMUS
University of Illinois at Chicago
Phase 4BBB
CYCLOSPORIN A
Fernanda P Silveira, MD, MS
Phase 4BBB
Rapamycin
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 3BB
Fludarabine
M.D. Anderson Cancer Center
Phase 3BB

View all 33 →

Same molecule, other indications

cc-5013 is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →